QLT makes board appointment
This article was originally published in Scrip
Executive Summary
QLT, a Canadian pharmaceutical company dedicated to the development and commercialisation of therapies for the eye, has appointed Joseph Turner to its board of directors and audit and risk committee. Mr Turner has more than 25 years' experience as a financial manager in the biotech and pharmaceutical industries. He was most recently chief financial officer at Myogen, which he joined in 1999, remaining until the company was acquired by Gilead Sciences in 2006.